ADK.V - DIAGNOS Inc.

TSXV - TSXV Real Time Price. Currency in CAD
0.3300
-0.0050 (-1.49%)
At close: 03:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.3350
Open0.3300
Bid0.3300 x 0
Ask0.3350 x 0
Day's Range0.3250 - 0.3300
52 Week Range0.1300 - 0.4500
Volume68,775
Avg. Volume111,547
Market Cap22.926M
Beta (5Y Monthly)-0.09
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateJul 11, 2023 - Jul 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    DIAGNOS Announces Closing of Private Placement and Exercise of Stock Warrants

    BROSSARD, Quebec, May 18, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a Canadian corporation active in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the closing, today, of a non-brokered private placement (“Private Placement”) of unsecured convertible debentures (each a “Debenture”) and stock warrants (each a “Warrant”) for gross proceeds of $865,000.

  • GlobeNewswire

    DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”

    IRIS-ai powered by DIAGNOS IRIS-ai powered by DIAGNOS BROSSARD, Quebec, May 17, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the launch of “IRIS-ai powered by DIAGNOS” by IRIS, The Visual Group, in partnership with DIAGNOS. For over two years, IRIS and DIAGNOS have joined forces

  • GlobeNewswire

    DIAGNOS and ÉTS Unveil a Method to Adapt Deep Learning Algorithms According to the Diversity of Contexts

    Diagnos - Domain Adaptation Method Diagnos - Domain Adaptation Method BROSSARD, Quebec, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) is one of the leaders in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI). DIAGNOS and École de Technologie Supérieure (ÉTS), a world-renowned technical university, are proud to announce the unveiling of a method for adapt

  • GlobeNewswire

    DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023

    Section of the eye Section of the eye BROSSARD, Quebec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) is a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI). DIAGNOS and École de Technologie Supérieure (ÉTS), a world-renowned technical university, are proud to announce that they will be presenting the results of their ground-breaking research on

  • GlobeNewswire

    DIAGNOS Announces Grant of Stock Options

    BROSSARD, Quebec, Feb. 10, 2023 (GLOBE NEWSWIRE) -- February 10, 2023 – Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the grant of an aggregate number of 1,275,000 stock options to its officers, employees, consultants and directors. Stock options vest at 50% per year, commencing with the first anniversary of the grant. Th

  • GlobeNewswire

    DIAGNOS Gets the Green Light for the Use of its Diabetic Retinopathy Screening Technology in Quebec Hospitals

    DIagnos Gets Approval for Quebec Hospitals DIagnos Gets Approval for Quebec Hospitals BROSSARD, Quebec, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce that the Quebec government has given the green light to Diagnos' Artificial Intelligence (AI) technology to screen and as

  • GlobeNewswire

    DIAGNOS Announces Closing of Private Placement

    BROSSARD, Quebec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces the closing, today, of a non-brokered private placement (“Private Placement”) of 5 units (each a “Unit”) issued at a price of $50,000 per Unit for gross proceeds of $250,000. For the period of November 25, 2022 to this date,

  • GlobeNewswire

    DIAGNOS Provides Additional Information to the Closing of Private Placement

    BROSSARD, Quebec, Dec. 15, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces that in connection with the closing of the private placement announced on December 12, 2022, the Corporation paid a cash commission of $9,000 to one qualified person (“Finder”) and issued 40,909 finder’s warrants to the Finde

  • GlobeNewswire

    DIAGNOS Enters the Retinal Diagnostics Market With its New 3D Image Analysis Technology

    Retina Scanning Retina Scanning BROSSARD, Quebec, Oct. 27, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is proud to announce it is entering the fast-growing retinal diagnostics market, armed with its new 3D image analysis technology. DIAGNOS is pushing the boundaries of the practice with a deep learni

  • GlobeNewswire

    DIAGNOS Receives Regulatory Approval from the Costa Rica Health Agency for its Artificial Intelligence Enabled Pathology Detection Systems

    BROSSARD, Quebec, Aug. 18, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is proud to announce the receipt of approval from the Costa Rican regulatory agency (Ministerio de Salud) for its Artificial Intelligence enabled Pathology Detection Systems. DIAGNOS’ platform has been approved for having complied

  • GlobeNewswire

    DIAGNOS Continues Expansion in Canada with Kick-off of Services in Endocrinology Clinics with Distribution Partner Labtician Ophthalmics

    BROSSARD, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is proud to continue its expansion in Canada with the kick-off of its services in endocrinology clinics with distribution partner Labtician Ophthalmics. DIAGNOS is announcing the kick-off by Labtician Ophthalmics (“Labtician”) of

  • GlobeNewswire

    DIAGNOS Announces the Start of the Deployment of its Pathology Detection Systems in the Retail Clinics of Farmacias Benavides, a Member of Walgreens Boots Alliance

    BROSSARD, Quebec, June 23, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the start of the deployment of its pathology detection systems in the retail clinics of Farmacias Benavides, a member of Walgreens Boots Alliance. “Following the signing of the agreement between DIAGNOS and

  • GlobeNewswire

    DIAGNOS Announces the Deployment of its Age-Related Macular Degeneration Detection Application Into the Optometry Clinics of IRIS, The Visual Group

    BROSSARD, Quebec, June 07, 2022 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the deployment of its Age-Related Macular Degeneration detection application into the optometry clinics of IRIS The Visual Group. It is with great pleasure that DIAGNOS is announcing the deployment of its Ag